Brentuximab vedotin plus bendamustine

a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen Maxted Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline chemotherapy. Achievement of complete remission (CR) with pre-ASCT salvage chemotherapy predicts favorable outcomes post-ASCT. This phase 1/2 study evaluated the combination of brentuximab vedotin (BV) plus bendamustine as a first salvage regimen in relapsed/ refractory HL. A total of 55 patients (28 primary refractory and 27 relapsed) were enrolled. Patients received BV (1.8 mg/kg) on day 1 and bendamustine (90 mg/m2) on days 1 and 2 of a 21-day cycle for up to 6 cycles. Patients could undergo ASCT any time after cycle 2. Following ASCT or completion of combination therapy if not proceeding to ASCT, patients could receive BV monotherapy for up to 16 cycles of total therapy. After a median of 2 cycles of combination therapy (range, 1-6), the objective response rate among 53 efficacy-evaluable patients was 92.5%, with 39 patients (73.6%) achieving CR. Forty patients underwent ASCT. Thirty-one patients (25 of whom underwent ASCT) received BV monotherapy (median, 10 cycles; range, 1-14). After a median of 20.9 months of follow-up, the estimated 2-year progression-free survival was 69.8% and 62.6% for patients who received ASCT and all patients, respectively. Thirty-one patients (56.4%) experienced infusion-related reactions (IRRs), with a majority occurring during cycle 2 of combination therapy. A protocol amendment requiring premedication reduced IRR severity. BV plus bendamustine as first salvage therapy in relapsed/refractory HL is highly active with a manageable toxicity profile. This trial was registered at www.clinicaltrials.gov as #NCT01874054.

Original languageEnglish (US)
Pages (from-to)40-48
Number of pages9
JournalBlood
Volume132
Issue number1
DOIs
StatePublished - Jul 5 2018

Fingerprint

Salvaging
Stem cells
Hodgkin Disease
Refractory materials
Stem Cell Transplantation
Chemotherapy
Bendamustine Hydrochloride
cAC10-vcMMAE
Drug Therapy
Salvage Therapy
Toxicity
Premedication
Therapeutics
Standard of Care
Disease-Free Survival

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

LaCasce, A. S., Gregory Bociek, R., Sawas, A., Caimi, P., Agura, E., Matous, J., ... Advani, R. (2018). Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood, 132(1), 40-48. https://doi.org/10.1182/blood-2017-11-815183

Brentuximab vedotin plus bendamustine : a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. / LaCasce, Ann S.; Gregory Bociek, R.; Sawas, Ahmed; Caimi, Paolo; Agura, Edward; Matous, Jeffrey; Ansell, Stephen Maxted; Crosswell, Howland E.; Islas-Ohlmayer, Miguel; Behler, Caroline; Cheung, Eric; Forero-Torres, Andres; Vose, Julie; O’Connor, Owen A.; Josephson, Neil; Wang, Yinghui; Advani, Ranjana.

In: Blood, Vol. 132, No. 1, 05.07.2018, p. 40-48.

Research output: Contribution to journalArticle

LaCasce, AS, Gregory Bociek, R, Sawas, A, Caimi, P, Agura, E, Matous, J, Ansell, SM, Crosswell, HE, Islas-Ohlmayer, M, Behler, C, Cheung, E, Forero-Torres, A, Vose, J, O’Connor, OA, Josephson, N, Wang, Y & Advani, R 2018, 'Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma', Blood, vol. 132, no. 1, pp. 40-48. https://doi.org/10.1182/blood-2017-11-815183
LaCasce, Ann S. ; Gregory Bociek, R. ; Sawas, Ahmed ; Caimi, Paolo ; Agura, Edward ; Matous, Jeffrey ; Ansell, Stephen Maxted ; Crosswell, Howland E. ; Islas-Ohlmayer, Miguel ; Behler, Caroline ; Cheung, Eric ; Forero-Torres, Andres ; Vose, Julie ; O’Connor, Owen A. ; Josephson, Neil ; Wang, Yinghui ; Advani, Ranjana. / Brentuximab vedotin plus bendamustine : a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. In: Blood. 2018 ; Vol. 132, No. 1. pp. 40-48.
@article{0a278eaa8fd142dc8c228714ff45e2fd,
title = "Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma",
abstract = "Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline chemotherapy. Achievement of complete remission (CR) with pre-ASCT salvage chemotherapy predicts favorable outcomes post-ASCT. This phase 1/2 study evaluated the combination of brentuximab vedotin (BV) plus bendamustine as a first salvage regimen in relapsed/ refractory HL. A total of 55 patients (28 primary refractory and 27 relapsed) were enrolled. Patients received BV (1.8 mg/kg) on day 1 and bendamustine (90 mg/m2) on days 1 and 2 of a 21-day cycle for up to 6 cycles. Patients could undergo ASCT any time after cycle 2. Following ASCT or completion of combination therapy if not proceeding to ASCT, patients could receive BV monotherapy for up to 16 cycles of total therapy. After a median of 2 cycles of combination therapy (range, 1-6), the objective response rate among 53 efficacy-evaluable patients was 92.5{\%}, with 39 patients (73.6{\%}) achieving CR. Forty patients underwent ASCT. Thirty-one patients (25 of whom underwent ASCT) received BV monotherapy (median, 10 cycles; range, 1-14). After a median of 20.9 months of follow-up, the estimated 2-year progression-free survival was 69.8{\%} and 62.6{\%} for patients who received ASCT and all patients, respectively. Thirty-one patients (56.4{\%}) experienced infusion-related reactions (IRRs), with a majority occurring during cycle 2 of combination therapy. A protocol amendment requiring premedication reduced IRR severity. BV plus bendamustine as first salvage therapy in relapsed/refractory HL is highly active with a manageable toxicity profile. This trial was registered at www.clinicaltrials.gov as #NCT01874054.",
author = "LaCasce, {Ann S.} and {Gregory Bociek}, R. and Ahmed Sawas and Paolo Caimi and Edward Agura and Jeffrey Matous and Ansell, {Stephen Maxted} and Crosswell, {Howland E.} and Miguel Islas-Ohlmayer and Caroline Behler and Eric Cheung and Andres Forero-Torres and Julie Vose and O’Connor, {Owen A.} and Neil Josephson and Yinghui Wang and Ranjana Advani",
year = "2018",
month = "7",
day = "5",
doi = "10.1182/blood-2017-11-815183",
language = "English (US)",
volume = "132",
pages = "40--48",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Brentuximab vedotin plus bendamustine

T2 - a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

AU - LaCasce, Ann S.

AU - Gregory Bociek, R.

AU - Sawas, Ahmed

AU - Caimi, Paolo

AU - Agura, Edward

AU - Matous, Jeffrey

AU - Ansell, Stephen Maxted

AU - Crosswell, Howland E.

AU - Islas-Ohlmayer, Miguel

AU - Behler, Caroline

AU - Cheung, Eric

AU - Forero-Torres, Andres

AU - Vose, Julie

AU - O’Connor, Owen A.

AU - Josephson, Neil

AU - Wang, Yinghui

AU - Advani, Ranjana

PY - 2018/7/5

Y1 - 2018/7/5

N2 - Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline chemotherapy. Achievement of complete remission (CR) with pre-ASCT salvage chemotherapy predicts favorable outcomes post-ASCT. This phase 1/2 study evaluated the combination of brentuximab vedotin (BV) plus bendamustine as a first salvage regimen in relapsed/ refractory HL. A total of 55 patients (28 primary refractory and 27 relapsed) were enrolled. Patients received BV (1.8 mg/kg) on day 1 and bendamustine (90 mg/m2) on days 1 and 2 of a 21-day cycle for up to 6 cycles. Patients could undergo ASCT any time after cycle 2. Following ASCT or completion of combination therapy if not proceeding to ASCT, patients could receive BV monotherapy for up to 16 cycles of total therapy. After a median of 2 cycles of combination therapy (range, 1-6), the objective response rate among 53 efficacy-evaluable patients was 92.5%, with 39 patients (73.6%) achieving CR. Forty patients underwent ASCT. Thirty-one patients (25 of whom underwent ASCT) received BV monotherapy (median, 10 cycles; range, 1-14). After a median of 20.9 months of follow-up, the estimated 2-year progression-free survival was 69.8% and 62.6% for patients who received ASCT and all patients, respectively. Thirty-one patients (56.4%) experienced infusion-related reactions (IRRs), with a majority occurring during cycle 2 of combination therapy. A protocol amendment requiring premedication reduced IRR severity. BV plus bendamustine as first salvage therapy in relapsed/refractory HL is highly active with a manageable toxicity profile. This trial was registered at www.clinicaltrials.gov as #NCT01874054.

AB - Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline chemotherapy. Achievement of complete remission (CR) with pre-ASCT salvage chemotherapy predicts favorable outcomes post-ASCT. This phase 1/2 study evaluated the combination of brentuximab vedotin (BV) plus bendamustine as a first salvage regimen in relapsed/ refractory HL. A total of 55 patients (28 primary refractory and 27 relapsed) were enrolled. Patients received BV (1.8 mg/kg) on day 1 and bendamustine (90 mg/m2) on days 1 and 2 of a 21-day cycle for up to 6 cycles. Patients could undergo ASCT any time after cycle 2. Following ASCT or completion of combination therapy if not proceeding to ASCT, patients could receive BV monotherapy for up to 16 cycles of total therapy. After a median of 2 cycles of combination therapy (range, 1-6), the objective response rate among 53 efficacy-evaluable patients was 92.5%, with 39 patients (73.6%) achieving CR. Forty patients underwent ASCT. Thirty-one patients (25 of whom underwent ASCT) received BV monotherapy (median, 10 cycles; range, 1-14). After a median of 20.9 months of follow-up, the estimated 2-year progression-free survival was 69.8% and 62.6% for patients who received ASCT and all patients, respectively. Thirty-one patients (56.4%) experienced infusion-related reactions (IRRs), with a majority occurring during cycle 2 of combination therapy. A protocol amendment requiring premedication reduced IRR severity. BV plus bendamustine as first salvage therapy in relapsed/refractory HL is highly active with a manageable toxicity profile. This trial was registered at www.clinicaltrials.gov as #NCT01874054.

UR - http://www.scopus.com/inward/record.url?scp=85048635308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048635308&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-11-815183

DO - 10.1182/blood-2017-11-815183

M3 - Article

VL - 132

SP - 40

EP - 48

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -